fluorodeoxyglucose f18 has been researched along with pazopanib in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Berney, D; Bex, A; Blank, C; Boleti, E; Chowdhury, S; Haanen, J; Jones, R; Kayani, I; Lim, L; Peters, J; Powles, T; Reynolds, AR; Sahdev, A; Shamash, J; Sharpe, K; Stewart, GD | 1 |
| Blomqvist, LK; Farnebo, J; Grybäck, P; Harmenberg, U; Laurell, A; Sandström, P; Ullén, A; Wersäll, P | 1 |
| Kaneko, T; Shinkai, M; Watanabe, K | 1 |
| Cho, A; Choi, YD; Hwang, SH; Kang, WJ; Rha, SY; Yun, M | 1 |
| Cook, G; Goh, V; Kelly-Morland, C; Mallett, S; Montana, G; Nathan, P; Rudman, S | 1 |
| Basturk, O; Corrias, G; Giancipoli, RG; Keohan, ML; Klimstra, D; Mannelli, L; Monti, S; Sawan, P; Schillaci, O | 1 |
| DE Geus-Oei, LF; Desar, IME; Grootjans, W; Koenen, AM; Oyen, WJ; Steeghs, N; VAN DER Graaf, WT; VAN Erp, NP; Verheijen, RB; Vlenterie, M | 1 |
| Fujiwara, K; Ishida, H; Kanamitsu, K; Shimada, A; Tsukahara, H; Washio, K | 1 |
2 trial(s) available for fluorodeoxyglucose f18 and pazopanib
| Article | Year |
|---|---|
A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Nephrectomy; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Radiopharmaceuticals; Sulfonamides; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Withholding Treatment | 2013 |
Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated
Topics: Adult; Aged; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Cell Proliferation; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Imidazoles; Indazoles; Indoles; London; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neoplasms, Second Primary; Positron-Emission Tomography; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome | 2017 |
6 other study(ies) available for fluorodeoxyglucose f18 and pazopanib
| Article | Year |
|---|---|
Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma.
Topics: Aged; Carcinoma, Renal Cell; Cone-Beam Computed Tomography; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Positron-Emission Tomography; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome | 2014 |
Autopsy case of pulmonary artery sarcoma forming aneurysm without FDG uptake.
Topics: Adult; Aneurysm; Aneurysm, Ruptured; Fatal Outcome; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Indazoles; Leiomyosarcoma; Lung; Male; Neoplasm Invasiveness; Positron-Emission Tomography; Pulmonary Artery; Pyrimidines; Radiopharmaceuticals; Rupture, Spontaneous; Shock, Hemorrhagic; Sulfonamides; Vascular Neoplasms | 2016 |
Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Pyrimidines; Pyrroles; Radiopharmaceuticals; Sorafenib; Sulfonamides; Sunitinib | 2017 |
Complete metabolic response to therapy of hepatic epithelioid hemangioendothelioma evaluated with 18F-fluorodeoxyglucose positron emission tomography/contrast-enhanced computed tomography: A CARE case report.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Fluorodeoxyglucose F18; Hemangioendothelioma, Epithelioid; Humans; Indazoles; Liver Neoplasms; Male; Positron Emission Tomography Computed Tomography; Pyrimidines; Radiopharmaceuticals; Sulfonamides; Treatment Outcome | 2018 |
Early Metabolic Response as a Predictor of Treatment Outcome in Patients With Metastatic Soft Tissue Sarcomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Indazoles; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Pyrimidines; Sarcoma; Sulfonamides; Treatment Outcome | 2019 |
A case of alveolar rhabdomyosarcoma showing concurrent responsive bone marrow lesions and refractory pancreatic lesions to pazopanib monotherapy.
Topics: Adolescent; Bone Density Conservation Agents; Bone Marrow; Bone Marrow Neoplasms; Fluorodeoxyglucose F18; Forkhead Box Protein O1; Humans; Indazoles; Oncogene Proteins, Fusion; Paired Box Transcription Factors; Pancreatic Neoplasms; PAX3 Transcription Factor; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Rhabdomyosarcoma, Alveolar; Sulfonamides; Tumor Microenvironment; Zoledronic Acid | 2020 |